Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In?

Pulmonx Corporation (NASDAQ:LUNG) is one of the best stocks under $3 to invest in. On October 28, Lake Street lowered the firm’s price target on Pulmonx to $4 from $8 and kept a Buy rating on the shares.

The firm believes that Wall Street will view the return of former CEO Glen French and CFO Derrick Sung positively. The shares are attractive due to the vast clinical proof of concept of Zephyr valves, the strong market opportunity, and the new product pipeline.

On the same day, Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Pulmonx and set a price target of $5.00. Additionally, John Young CFA from Canaccord Genuity maintained a Buy rating on Pulmonx, with a price target of $6.00.

Pulmonx Corporation (NASDAQ:LUNG) is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.

While we acknowledge the potential of LUNG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.